Publicaciones en colaboración con investigadores/as de Hospital Regional Universitario de Málaga (15)

2022

  1. Clinical characteristics, health care resource utilization and direct medical costs of Rotavirus hospitalizations in Spain (2013–2018)

    Human Vaccines and Immunotherapeutics, Vol. 18, Núm. 5

2021

  1. Rotavirus gastroenteritis hospitalizations in provinces with different vaccination coverage rates in Spain, 2013–2018

    BMC Infectious Diseases, Vol. 21, Núm. 1

2019

  1. Clinical practice update of antifungal prophylaxis in immunocompromised children

    Revista Espanola de Quimioterapia, Vol. 32, Núm. 5, pp. 410-425

  2. Immunisation schedule of the Spanish Association of Paediatrics: 2019 recommendations

    Anales de Pediatria, Vol. 90, Núm. 1, pp. 56.e1-56.e9

2017

  1. 2017 pneumococcal vaccine recommendations of the Spanish Association of Paediatrics. Authors reply

    Anales de Pediatria

2016

  1. Calendario de vacunaciones de la Asociación Española de Pediatría (CAV-AEP): recomendaciones 2016

    Anales de Pediatria, Vol. 84, Núm. 1, pp. 60.e1-60.e13

2015

  1. Decreased activation-induced cell death by EBV-transformed B-cells from a patient with autoimmune lymphoproliferative syndrome caused by a novel FASLG mutation

    Pediatric Research, Vol. 78, Núm. 6, pp. 603-608

  2. Neumonía adquirida en la comunidad: tratamiento ambulatorio y prevención

    Anales de Pediatria, Vol. 83, Núm. 6, pp. 439.e1-439.e7

  3. Vaccination against meningococcal B disease. Public statement of the Advisory Committee on Vaccines of the Spanish Association of Paediatrics (CAV-AEP)

    Anales de Pediatria, Vol. 82, Núm. 3, pp. 198.e1-198.e9

2012

  1. Five-year antibody persistence and safety following a booster dose of combined haemophilus influenzae type b-neisseria meningitidis serogroup c-tetanus toxoid conjugate vaccine

    Pediatric Infectious Disease Journal, Vol. 31, Núm. 10, pp. 1074-1077

2008

  1. Immunogenicity and reactogenicity of a booster dose of a novel combined haemophilus influenzae type b-neisseria meningitidis serogroup c-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age

    Pediatric Infectious Disease Journal, Vol. 27, Núm. 7, pp. 579-588

2007

  1. Immunogenicity and reactogenicity of primary immunization with a novel combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine coadministered with a diphtheria-tetanus- acellular pertussis-hepatitis B-inactivated poliovirus vaccine at 2, 4 and 6 months

    Pediatric Infectious Disease Journal, Vol. 26, Núm. 1, pp. 1-7

  2. Slow progression of human immunodeficiency virus and hepatitis C virus disease in a cohort of coinfected children

    Pediatric Infectious Disease Journal, Vol. 26, Núm. 9, pp. 846-849

2006

  1. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine

    Pediatric Infectious Disease Journal, Vol. 25, Núm. 8, pp. 713-720

2003

  1. Epidemiology and economic impact of varicella in immunocompetent children in Spain. A nation-wide study

    Vaccine, Vol. 21, Núm. 23, pp. 3236-3239